X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatric Neuroblastoma.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Product Name: CPP-1X-T
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Panbela Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Product Name: Iwilfin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Product Name: Iwilfin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Product Name: CPP-1X
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Panbela Therapeutics
Deal Size: $9.5 million Upfront Cash: Undisclosed
Deal Type: Divestment July 19, 2023
Details:
DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Norgine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 23, 2021
Details:
US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.
Lead Product(s): Lofexidine
Therapeutic Area: Psychiatry/Psychology Product Name: Lucemyra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Federal Emergency Management Agency
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 06, 2020
Details:
This acquisition significantly expands Supernus' business in CNS and increases and diversifies its revenue and earnings streams, while continuing to maintain a strong balance sheet.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: Apokyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 09, 2020
Details:
US WorldMeds obtained U.S. rights to commercialize and distribute the SYMJEPI products, upon the termination of Sandoz’ commercial rights, and ZIMHI.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Adamis Pharmaceuticals
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 11, 2020
Details:
Acquisition adds three products developed and sold in the U.S. market with a late-stage development candidate in the Supernus pipeline: APOKYN ®, MYOBLOC ® XADAGO ® and Apomorphine Infusion Pump.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: Apokyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $530.0 million Upfront Cash: $300.0 million
Deal Type: Acquisition April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
